Developing generic clinical trial animated explainer videos in the UK: results of a survey and case study.
Calvert C. et al, (2025), Trials, 26
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
Harris V. et al, (2025), Lancet infect dis, 25, 68 - 79
Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response
Drennan P. et al, (2024), Lancet microbe
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2.
Higham HE. et al, (2024), Br j clin pharmacol, 90, 1586 - 1599
PERI-operative biologic DMARD management: Stoppage or COntinuation during orthoPaEdic operations (the PERISCOPE trial) - a study protocol for a pragmatic, UK multicentre, superiority randomised controlled trial with an internal pilot, economic evaluation and nested qualitative study.
Brady S. et al, (2024), Bmj open, 14
Current usage of explainer animations in trials: a survey of the UKCRC registered clinical trial units in the UK.
Barber VS. et al, (2024), Trials, 25
Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases.
Kawano-Dourado L. et al, (2024), Thorax
Use of oxygen-loaded nanobubbles to improve tissue oxygenation: Bone-relevant mechanisms of action and effects on osteoclast differentiation.
Knowles HJ. et al, (2024), Biomaterials, 305
Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients
Standing JF. et al, (2024), Nature communications, 15
Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungs.
Weeratunga P. et al, (2023), Nat commun, 14
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.
Gbinigie O. et al, (2023), Bmj open, 13
In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.
Drennan PG. et al, (2023), Clin transl sci, 16, 357 - 382